Chimeric antigen-receptor (CAR) T cells: The revolution of the cell and personalized therapy for cancer

Chimeric antigen-receptor (CAR) T cells: The revolution of the cell and personalized therapy for cancer

-

Saved in:

Bibliographic Details
Main Author:	Javier Briones-Meijide
Format:	Article
Language:	English
Published:	Elsevier 2019-11-01
Series:	Farmacia Hospitalaria
Online Access:	http://www.aulamedica.es/fh/pdf/11312.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy
by: C. Carcopino, et al.
Published: (2024-12-01)

Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
by: Eugenio Galli, et al.
Published: (2021-10-01)

Chimeric antigen receptor T-cell therapy in autoimmune diseases
by: Jie Liu, et al.
Published: (2024-11-01)

Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies
by: Haiqiong Zheng, et al.
Published: (2024-11-01)

Hepatic T cell lymphoma after chimeric antigen receptor T cell therapy for myeloma
by: Joshua Mehr, et al.
Published: (2024-12-01)

The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances
by: Pin Yao, et al.
Published: (2024-12-01)

CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA
by: Ugo Testa, et al.
Published: (2024-10-01)

Targeting CEA in metastatic triple negative breast cancer with image-guided radiation followed by Fab-mediated chimeric antigen receptor (CAR) T-cell therapy
by: Eric Aniogo, et al.
Published: (2024-12-01)

From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy
by: E. Pinto, et al.
Published: (2025-01-01)

Updates on Chimeric Antigen Receptor T-Cells in Large B-Cell Lymphoma
by: Khalil Saleh, et al.
Published: (2024-12-01)

Defining ‘Intention’ in intention-to-treat survival outcomes for chimeric antigen receptor T-cell therapy
by: Charles J. Milrod, et al.
Published: (2025-02-01)

Chimeric antigen receptor T cells targeting CD312 as a therapy for acute myeloid leukemia
by: Danni Xie, et al.
Published: (2025-01-01)

Procalcitonin level threshold and antibiotic use in patients receiving chimeric antigen receptor T-cell therapy
by: Murari Ramesh, et al.
Published: (2024-12-01)

Genome Editing as a Vehicle to Drive Successful Chimeric Antigen Receptor T Cell Therapies to the Clinic
by: Caitlin R Hopkins, et al.
Published: (2021-12-01)

Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review
by: Joseph Sassine, et al.
Published: (2025-01-01)

Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy
by: Alexander P. Boardman, et al.
Published: (2024-11-01)

Recommendations for the timing, dosage, and usage of corticosteroids during cytokine release syndrome (CRS) caused by chimeric antigen receptor (CAR)-T cell therapy for hematologic malignancies
by: Sanfang Tu, et al.
Published: (2024-11-01)

Preclinical evaluation of chimeric antigen receptor T cells targeting the carcinoembryonic antigen as a potential immunotherapy for gallbladder cancer
by: Ernesto Lopez, et al.
Published: (2023-12-01)

Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects
by: Yelei Guo, et al.
Published: (2016-01-01)

Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells
by: Pavel Otáhal, et al.
Published: (2016-04-01)

Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas
by: Gohar S. Manzar, et al.
Published: (2025-01-01)

Advancing Chimeric Antigen Receptor T-Cell Therapy for Acute Myeloid Leukemia: Current Limitations and Emerging Strategies
by: Daniela Damiani, et al.
Published: (2024-12-01)

The advent of chimeric antigen receptor T Cell therapy in recalibrating immune balance for rheumatic autoimmune disease treatment
by: Qianyu Guo, et al.
Published: (2024-12-01)

Siltuximab for chimeric antigen receptor T-cell therapy–related CRS and ICANS: a multicenter retrospective analysis
by: Amneet Bajwa, et al.
Published: (2025-01-01)

Advancements and Future Directions of Dual-Target Chimeric Antigen Receptor T-Cell Therapy in Preclinical and Clinical Studies
by: Chenyun Zhang, et al.
Published: (2025-01-01)

Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell administration
by: Alice Sýkorová, et al.
Published: (2024-09-01)

Sensitive manipulation of CAR T cell activity using a chimeric endocytosing receptor
by: Xin Liu, et al.
Published: (2020-10-01)

Chimeric antigen receptor with novel intracellular modules improves antitumor performance of T cells
by: Pengju Wang, et al.
Published: (2025-01-01)

Neuropsychiatric manifestations following chimeric antigen receptor T cell therapy for cancer: a systematic review of clinical outcomes and management strategies
by: Max Topp, et al.
Published: (2024-12-01)

The nuclear factor-κ B inhibitor SN50 enhances the efficacy of B-cell maturation antigen-targeted chimeric antigen receptor T-cell therapy
by: Jinlan Long, et al.
Published: (2025-01-01)

Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma
by: Hui-Ju Hsieh, et al.
Published: (2025-03-01)

Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment
by: Rahul Navab, et al.
Published: (2025-01-01)

In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy
by: Weiyue Zhang, et al.
Published: (2024-11-01)

CD19-directed chimeric antigen receptor T-cell therapy: what can we learn from the haematologist?
by: Marie José Kersten, et al.
Published: (2025-01-01)

Deletion of CD38 enhances CD19 chimeric antigen receptor T cell function
by: Kimberly Veliz, et al.
Published: (2024-06-01)

Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects
by: Mehdi Alidadi, et al.
Published: (2024-11-01)

CD19‐targeting chimeric antigen receptor T‐cell therapy is safe and effective for intra‐cardiac B cell non‐Hodgkin lymphoma
by: Daniel H. Chen, et al.
Published: (2024-12-01)

Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma
by: Chengcheng Zhang, et al.
Published: (2023-05-01)

High-affinity chimeric antigen receptor signaling induces an inflammatory program in human regulatory T cells
by: Russell W. Cochrane, et al.
Published: (2024-12-01)

Cytokine release syndrome after chimeric antigen receptor T cell therapy in patients with diffuse large B-cell lymphoma: a systematic review
by: Andressa Rodrigues dos Santos, et al.
Published: (2024-12-01)